enasidenib
Selected indexed studies
- Enasidenib. (, 2012) [PMID:31643811]
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. (Blood, 2017) [PMID:28588020]
- Enasidenib. (, 2006) [PMID:29999984]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Enasidenib. (2012) pubmed
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. (2017) pubmed
- Enasidenib. (2006) pubmed
- Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. (2023) pubmed
- Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. (2021) pubmed
- Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. (2021) pubmed
- Enasidenib and ivosidenib in AML. (2020) pubmed
- Enasidenib: First Global Approval. (2017) pubmed
- Enasidenib for the treatment of acute myeloid leukemia. (2018) pubmed
- Enasidenib. (2018) pubmed